Glaxo to pay up to $3 billion for sleep-disorder drug

LONDON (MarketWatch) - GlaxoSmithKline on Monday announced a deal to pay as much as $3 billion to Switzerland's Actelion to license a sleep-disorder drug in yet another example of a major drug firm turning to a smaller rival to build out pipelines. FULL STORY

I wonder if the sleep disorder tablet will be of any use to me? Since I stopped taking Seroxat my sleep is all over the place!

It's no fun sleeping in phone boxes, cabs, trains, buses and no fun waking at 3am knowing that I have no chance getting back to sleep!

Oh I wish I had the power of hindsight. I would never had taken Seroxat!

I also wish I had as much money to throw around as GlaxoSmithKline do!

Fid

Hat tip: Pharmagossip

Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING

AVAILABLE FOR DOWNLOAD HERE


PAPERBACK COMING SOON